Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. filed a Form 8-K dated August 28, 2023, under Item 5.02 regarding amendments to executive employment agreements. The company’s common stock trades on the Nasdaq Capital Market under the symbol MIRA.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes
- Effective August 28, 2023, Chief Executive Officer Erez Aminov’s annual base salary was increased to $200,000.
- Mr. Aminov also became entitled to an additional payment reflecting the difference between the new salary and his prior base salary, retroactive to August 1, 2023.
- An amendment clarified that Executive Chairman Dr. Chris Chapman’s employment is on a part-time, as-needed basis.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or business outlook. The increased CEO compensation is expected to raise personnel expenses, although the filing does not quantify the total additional cost. The filing does not identify material contingencies or other unusual items.
Important Facts to Verify
- Review Exhibits 10.1 and 10.2 for the complete compensation terms and any additional provisions.
- Confirm the amount of the retroactive salary adjustment owed to Mr. Aminov based on his prior base salary.
- Assess the effect of the executive compensation changes on future operating expenses and liquidity in subsequent filings.
- Monitor later filings for updates regarding Dr. Chapman’s part-time responsibilities and compensation.